Evidence map›Paper›PMID 39988871›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience.

Joan Roig-Soriano, Ángel Edo, Sergi Verdés, Carlos Martín-Alonso, Cristina Sánchez-de-Diego, Laura Rodriguez-Estevez, Antonio L Serrano, Carmela R Abraham, Assumpció Bosch, Francesc Ventura and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. [Potential of early diagnosis and targeted therapy for Klotho protein in chronic kidney disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Joan Roig-SorianoInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
Ángel EdoInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
Sergi VerdésInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
Carlos Martín-AlonsoInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Cristina Sánchez-de-DiegoVall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
Laura Rodriguez-EstevezInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
Antonio L SerranoDepartment of Medicine and Life Sciences, Pompeu Fabra University, 08003 Barcelona, Spain; Altos Labs, San Diego Institute of Science, San Diego, CA 92122, USA.
Carmela R AbrahamADvantage Therapeutics, Inc., Miami, FL 33127, USA.
Assumpció BoschInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain; Ciberned, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Francesc VenturaIDIBELL, Universitat de Barcelona, 08908 Barcelona, Spain.
Bryen A JordanDominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, NY 10461, USA.
Pura Muñoz-CánovesDepartment of Medicine and Life Sciences, Pompeu Fabra University, 08003 Barcelona, Spain; ICREA, 08010 Barcelona, Spain; Altos Labs, San Diego Institute of Science, San Diego, CA 92122, USA.
Miguel ChillónInstitut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain; ICREA, 08010 Barcelona, Spain; Unitat de Producció de Vectors (UPV), Universitat Autònoma de Barcelona, 08193 Barcelona, Spain. Electronic address: miguel.chillon@uab.es.

Funding

SUPPORT FOR THE ROSE F KENNEDY IDDRC P50P50HD105352 · NICHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SOPHIE MOLHOLM, Steven Upshaw Walkley · 2021 to 2026
$7.0M
NICHD NIH HHS P50 HD105352
6 · The paper itself

Abstract

Aging is a major risk factor for pathologies including sarcopenia, osteoporosis, and cognitive decline, which bring suffering, disability, and elevated economic and social costs. Therefore, new therapies are needed to achieve healthy aging. The protein Klotho (KL) has emerged as a promising anti-aging molecule due to its pleiotropic actions modulating insulin, insulin-like growth factor-1, and Wnt signaling pathways and reducing inflammatory and oxidative stress. Here, we explored the anti-aging potential of the secreted isoform of this protein on the non-pathological aging progression of wild-type mice. The delivery of an adeno-associated virus serotype 9 (AAV9) coding for secreted KL (s-KL) efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan. Notably, KL treatment improved physical fitness, related to a reduction in muscle fibrosis and an increase in muscular regenerative capacity. KL treatment also improved bone microstructural parameters associated with osteoporosis. Finally, s-KL-treated mice exhibited increased cellular markers of adult neurogenesis and immune response, with transcriptomic analysis revealing induced phagocytosis and immune cell activity in the aged hippocampus. These results show the potential of elevating s-KL expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span.

Indexed as

GlucuronidaseLongevityAgingAnimalsDependovirusGenetic VectorsHippocampusKlotho ProteinsMaleMiceNeurogenesisSarcopeniaGlucuronidaseKlotho ProteinsAAVanti-agingboneKlotholongevitymuscleneuroinflammationosteoporosissarcopenia

Identifiers

PMID39988871
PMCPMC11997498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.